Related by context. All words. (Click for frequent words.) 74 nonfatal MI 73 secondary efficacy endpoint 72 secondary efficacy endpoints 72 myocardial infarction stroke 70 secondary endpoint 69 nonfatal myocardial infarction 69 symptomatic VTE 68 ischemic cardiomyopathy 68 definite stent thrombosis 68 eplerenone 68 efficacy endpoint 68 cerebrovascular events 68 binary restenosis 68 reinfarction 67 prospectively defined 67 acute coronary syndromes ACS 67 Primary endpoints 67 ipsilateral stroke 67 primary endpoint 66 secondary endpoints 66 MACCE 66 prespecified 66 HF hospitalization 66 recurrent ischemia 66 thromboembolic events 66 events MACE 66 morphometric vertebral fractures 66 cardiovascular hospitalization 66 bivalirudin 66 nonfatal stroke 66 IIIa inhibitor 66 Secondary endpoints 66 coronary revascularization 66 primary efficacy endpoint 66 periprocedural 66 Thrombolysis 65 angiographic outcomes 65 TRITON TIMI 65 myocardial infarction MI 65 irbesartan 65 FOLFIRI 65 TEAEs 65 active comparator 65 Events MACE 65 nonrandomized 65 RE LY ® 65 XIENCE V PROMUS Stent 65 chlorambucil 65 rFVIIa 65 tolvaptan 65 death reinfarction 65 treatment emergent adverse 65 efficacy endpoints 65 systemic embolism 65 noninferiority 65 prespecified secondary 65 repeat revascularization 65 thromboembolic 64 ATACAND 64 TAXUS Express Stent 64 rosuvastatin #mg 64 idraparinux 64 antithrombotics 64 STRIDE PD 64 clinical endpoints 64 thrombolytic agents 64 cardiovascular hospitalizations 64 FOLPI 64 Index CDAI 64 unfractionated heparin 64 febrile neutropenia 64 dacarbazine 64 thromboembolic complications 64 Doxil ® 64 TIMI 63 #mg BID [003] 63 CYPHER ® Stent 63 QTc prolongation 63 melphalan prednisone 63 ExTRACT TIMI 63 LVEF 63 mycophenolate mofetil 63 Secondary efficacy endpoints 63 macrovascular events 63 cangrelor 63 achieved statistical significance 63 MoxDuo TM IR 63 target vessel revascularization 63 elotuzumab 63 hematologic toxicity 63 ARCOXIA 63 severe exacerbations 63 cilostazol 63 Crohn Disease Activity 63 neoadjuvant 63 fondaparinux 63 virologic failure 63 nab paclitaxel 63 NYHA Class II 63 comparator arm 63 EURIDIS 63 oxycodone CR 63 APTIVUS r 63 mg BID dose 63 doxorubicin docetaxel 63 5-FU/LV 63 revascularization procedures 63 resuscitated cardiac arrest 63 TAXUS Stent 63 recurrent DVT 63 pegylated interferon alfa 2b 63 fatal myocardial infarction 62 ARIXTRA 62 eptifibatide 62 LOVENOX 62 periprocedural MI 62 desvenlafaxine succinate 62 MEND CABG II 62 carboplatin paclitaxel 62 NATRECOR ® 62 MADRS score 62 mcg BID 62 NATRECOR R 62 thromboembolism 62 recurrent VTE 62 oral diclofenac 62 pegylated liposomal doxorubicin 62 infarct size 62 ABC/3TC 62 ximelagatran 62 teriflunomide 62 serum phosphorous 62 valsartan 62 BENICAR HCT 62 chemoradiotherapy 62 Amrubicin 62 CANCIDAS 62 tanespimycin 62 mcg QD 62 limiting toxicity 62 lymphopenia 62 CYPHER Stent 62 Fludara 62 recurrent glioblastoma multiforme 62 RE LY 62 Kaplan Meier analysis 62 patients undergoing percutaneous 62 Erythropoietic therapies may 62 posaconazole 62 pharmacokinetics PK 62 DAPT 62 nadolol 62 β blockers 62 sirolimus eluting stent 62 discontinuations due 62 cytopenias 62 aldosterone antagonist 62 mcg albinterferon alfa 2b 62 nonfatal myocardial infarction MI 62 adjunctive placebo 62 postoperative chemotherapy 62 arterial thromboembolic events 62 surrogate endpoint 62 evaluable 62 non inferiority 62 Montgomery Asberg Depression 62 lipid lowering agents 62 trials RCTs 62 antiplatelet agents 62 dosage regimens 62 antiarrhythmic drug 62 paclitaxel eluting stents 62 CR nPR 62 recurrent venous thromboembolism 62 Secondary endpoints included 62 genotypic resistance 62 aspirin clopidogrel 62 tapentadol ER 62 myocardial infarctions 62 pericardial effusion 62 everolimus eluting stents 62 viral kinetic 61 enoxaparin 61 coronary stenosis 61 ARB telmisartan 61 boosted protease inhibitor 61 events AEs 61 concomitant medications 61 target lesion revascularization 61 XIENCE V demonstrated 61 unfractionated heparin UFH 61 HCV SPRINT 61 non valvular atrial 61 zonisamide SR 61 ACTEMRA TM 61 pCR 61 Keppra R 61 insulin detemir 61 postoperative complication 61 Response Evaluation Criteria 61 PREZISTA r 61 Folfox 61 endoscopic remission 61 GOUT 61 CIMZIA TM certolizumab pegol 61 NIHSS score 61 DOXIL 61 abacavir lamivudine 61 patients evaluable 61 docetaxel chemotherapy 61 salmeterol fluticasone 61 GP IIb IIIa inhibitor 61 lopinavir r arm 61 mg kg dose 61 pertuzumab 61 dose cohorts 61 cytogenetic response 61 severe neutropenia 61 ertapenem 61 placebo controlled randomized 61 Nesiritide 61 refractory AML 61 stroke myocardial infarction 61 certolizumab 61 PASI scores 61 peginterferon alfa 2b 61 extrapyramidal symptoms 61 prospective multicenter randomized 61 infusional 61 partial remissions 61 postintervention 61 laboratory abnormalities 61 calcineurin inhibitor 61 glycated hemoglobin levels 61 placebo controlled clinical 61 nonoperative 61 antiplatelet agent 61 oral allopurinol 61 relapsed refractory multiple myeloma 61 Rating Scale MADRS 61 unresectable HCC 61 bosentan 61 CYPHER R Sirolimus eluting 61 nonoperative treatment 61 ACUITY trial 61 CorVue ™ 61 myocardial infarction 61 cardiovascular morbidity 61 gemcitabine Gemzar 61 ribavirin RBV 60 Major Adverse Cardiac 60 VELCADE melphalan 60 carotid endarterectomy CEA 60 multicentre randomized 60 azacitidine 60 locoregional recurrence 60 VAPRISOL 60 MGd 60 graft dysfunction 60 lispro 60 virologic response 60 upper gastrointestinal bleeding 60 dose regimens 60 confidence interval CI 60 dosing cohorts 60 HAMD 60 NPH insulin 60 angiotensin converting enzyme inhibitors 60 alteplase 60 vandetanib 60 TNF antagonists 60 plus gemcitabine 60 SVR# 60 prospective multicenter 60 TAXUS VI 60 virologic breakthrough 60 TAXUS stent 60 subgroup analyzes 60 haematologic 60 revascularizations 60 mg BID 60 p = #.# [003] 60 virological failure 60 acute myocardial infarction AMI 60 FOLFOX6 60 clevidipine 60 subanalysis 60 carotid artery stenting CAS 60 Percutaneous Coronary Intervention 60 LEXIVA r 60 placebo controlled trials 60 chemoradiation 60 pain palliation 60 mcg kg 60 dose limiting toxicities 60 galiximab 60 antithrombotic 60 leukopenia 60 ischemic complications 60 QTc 60 cyclophosphamide methotrexate 60 biochemical recurrence 60 CCyR 60 primary endpoints 60 #mg BID [001] 60 evaluable subjects 60 Serious adverse reactions 60 colorectal adenoma 60 mitomycin 60 Carotid Revascularization Endarterectomy vs. 60 venous thromboembolic events 60 metastatic HRPC 60 ticagrelor 60 TAXUS Liberte Stent 60 clinically meaningful improvement 60 zotarolimus eluting stent 60 SYNTAX trial 60 peripheral sensory neuropathy 60 liver transplant recipients 60 KRAS mutations occur 60 thrombotic events 60 clopidogrel Plavix 60 LPV r 60 mg QD 60 IV NSCLC 60 interferon alfa 60 prognostic variables 60 abciximab 60 CIMZIA ™ 60 HBeAg seroconversion 60 hematologic adverse 60 serum urate 60 FOLFOX 60 Natalizumab 60 hemorrhagic complications 60 edoxaban 60 saline placebo 60 intima media thickness 60 TORISEL 60 dose cohort 60 tirofiban 60 postoperative AF 60 gout flares 60 RECIST Response Evaluation Criteria 60 MAGE A3 ASCI 60 infusional 5-FU/LV 60 mg dose 60 daunorubicin 60 4mg/kg 60 atherothrombotic disease 60 nonsignificant 60 nonresponders 60 Solid Tumors criteria 60 Randomized Evaluation 60 biologic DMARD 60 retinal thickness 60 virological response 60 remission CR 60 rosuvastatin 60 Hazard Ratio 60 plus dexamethasone 60 FOLFOX4 60 ACE inhibitor ramipril 60 Fibrin Pad 60 aflibercept 60 cardiac dysfunction 60 primary efficacy endpoints 59 Navelbine 59 hyperalgesia 59 rt PA 59 LHRH antagonists 59 prospective randomized controlled 59 NOXAFIL 59 tiotropium 59 univariate 59 INTEGRILIN 59 CYPHER ® 59 statistically significant p = 59 CsA 59 olmesartan 59 mitoxantrone 59 CR CRu 59 dabigatran etexilate 59 transurethral resection 59 hypercalcemia 59 inhibitor RG# 59 serum phosphorus 59 Kaplan Meier curves 59 dextromethorphan quinidine 59 aspartate aminotransferase AST 59 undetectable HBV DNA 59 NEVO ™ 59 locoregional 59 sirolimus eluting stents 59 invasive candidiasis 59 macrovascular 59 angiographic restenosis 59 ivabradine 59 placebo controlled Phase III 59 histologic subtype 59 fluvastatin 59 subtrochanteric 59 nondiabetic patients 59 levosimendan 59 p = NS 59 HDRS 59 PEGINTRON TM 59 timepoints 59 #mg QD [002] 59 Hycamtin ® 59 COPEGUS 59 Ceplene/IL-2 59 DU #b 59 CRp 59 tumor lysis syndrome 59 pyrexia mucositis sepsis febrile 59 octreotide LAR 59 ruboxistaurin 59 NMIBC 59 metastatic GIST 59 candesartan 59 pharmacokinetic equivalence 59 oral rivaroxaban 59 Ranolazine 59 incidence ≥ 59 F FDG PET 59 ALT flares 59 TAXUS Liberte Long 59 ACTEMRA 59 Free Survival PFS 59 metastatic CRC 59 unstable angina UA 59 thromboprophylaxis 59 gastrointestinal perforation 59 ST elevation myocardial 59 ACCORD Lipid 59 relapsed MM 59 creatinine clearance 59 antithrombotic therapy 59 neurologic progression 59 generalized seizures 59 headache nasopharyngitis 59 liver histology 59 myocardial ischemia 59 TMC# r 59 postoperative mortality 59 ischemia driven 59 DMARD 59 chlorthalidone 59 endometrial hyperplasia 59 intra arterial 59 lopinavir r 59 telaprevir dosed 59 exploratory endpoints 59 CDAI 59 iniparib 59 candesartan cilexetil 59 enoximone 59 calcineurin inhibitors 59 adalimumab 59 NYHA Class III 59 logistic regression models 59 AZOR 59 SYNTAX 59 ribavirin therapy 59 relapsed MCL 59 LMWH 59 antihypertensive agents 59 plasma kallikrein inhibitor 59 salmeterol fluticasone propionate 59 placebo dexamethasone 59 conditional logistic regression 59 lenalidomide dexamethasone 59 Taxus Stent 59 double blinded placebo 59 brivaracetam 59 noninferior 59 echocardiographic 59 ritonavir boosted lopinavir 59 placebo controlled clinical trials 59 COPD exacerbation 59 EXJADE 59 idarubicin 59 prospectively stratified 59 TAVR 59 randomized multicenter 59 HCV RESPOND 2 59 PEG INTRON 59 lumiracoxib 59 pharmacokinetic parameters 59 #.#/#.# mmHg [001] 59 nesiritide 59 mcg doses 59 placebo controlled studies 59 glycoprotein IIb IIIa inhibitor 59 HBeAg positive patients 59 paroxetine Paxil 59 platelet reactivity 59 left ventricular dysfunction 59 sunitinib malate 59 sustained virological response 59 statistical significance p 59 HbA1c levels 59 sirolimus stent 59 free survival PFS 59 hepatotoxicity 59 Candesartan 59 RECIST criteria 59 analgesic efficacy 59 5-fluorouracil/leucovorin 59 lipid lowering drugs 59 MERLIN TIMI 59 palonosetron 59 Operative mortality 59 randomized blinded 59 simvastatin ezetimibe 59 timepoint 59 Alzheimer Disease Assessment 59 NYHA functional class 59 evaluable patients 59 somatostatin analog 59 PSADT 59 recurrent myocardial infarction 59 glatiramer acetate 59 PRADAXA 59 mm Stent 59 PEG IFN 59 nonvertebral fracture 59 urate lowering therapy 59 direct thrombin inhibitors 59 TNF antagonist 59 hemodynamically significant 59 nicardipine 59 plus ribavirin 59 Myocardial Infarction Study 59 pharmacodynamic effects 59 velafermin 58 CHAMPION PCI 58 MEND CABG 58 clinico pathological 58 MoxDuo IR 58 Secondary endpoints include 58 Xelox 58 tipranavir r 58 Psoriasis Area 58 neutropenia dehydration dyspnea 58 pulmonary embolism PE 58 fenofibric acid 58 vinorelbine 58 ug dose 58 proximal DVT 58 paclitaxel carboplatin 58 HbA 1c levels 58 oral anticoagulant 58 peginterferon alfa 58 decitabine 58 placebo p = 58 non selective NSAIDs 58 tecarfarin 58 Scale EDSS 58 esophageal carcinoma 58 GAMMAGARD 58 adenoma recurrence 58 renal dysfunction 58 plasma pharmacokinetics 58 tenofovir emtricitabine 58 PROMACTA 58 fallopian tube cancers 58 invasive aspergillosis 58 low dose cytarabine 58 clodronate 58 patients undergoing CABG 58 Montgomery Åsberg Depression 58 neoadjuvant chemotherapy 58 otamixaban 58 phase IIb clinical 58 deferiprone 58 trastuzumab emtansine T DM1 58 INC# 58 intravenous diuretics 58 urate lowering 58 CIMZIA TM 58 variceal 58 enalapril 58 sirolimus eluting 58 MIRAPEX 58 Jevtana 58 sustained virologic response 58 baseline HbA1c 58 unstable angina pectoris 58 BRIM2 58 CA4P 58 MYDICAR 58 6R BH4 58 oral antidiabetes drugs 58 riociguat 58 alkylating agent 58 mRCC 58 Lenalidomide 58 intravenous cyclophosphamide 58 ezetimibe simvastatin 58 P = .# 58 EDEMA3 58 trial evaluating PRX# 58 LV dysfunction 58 stroke transient ischemic 58 apremilast 58 HAM D# 58 atherothrombotic 58 zolmitriptan 58 TELCYTA 58 hemostatic efficacy 58 BEXXAR Therapeutic Regimen 58 Acute Ischemic Stroke 58 PREZISTA r arm 58 ICD implantation 58 Elitek 58 dose cytarabine 58 lumbar spine BMD 58 FOLFOX regimen 58 AGILECT ® 58 primary hypercholesterolemia 58 hypoglycemic events 58 platelet inhibition 58 tipranavir 58 opioid induced bowel dysfunction 58 macroalbuminuria 58 AGGRASTAT R 58 angina pectoris 58 NRTI 58 vertebral fracture 58 PAOD 58 Adverse events 58 epoetin alfa 58 caspofungin 58 ancrod 58 heparin induced thrombocytopenia 58 curative resection 58 R# #mg BID 58 HBeAg negative patients 58 atazanavir ritonavir 58 Vidaza azacitidine 58 peginterferon alfa 2a 58 Hb A1C 58 coadministration 58 tolerated dose MTD 58 Androxal TM 58 MYCAMINE 58 OPAXIO 58 rFSH 58 antiplatelet drugs 58 VADT 58 oral anticoagulation 58 thrombotic complications 58 everolimus eluting stent 58 icatibant 58 oral vancomycin 58 docetaxel Taxotere ® 58 statistically significant reduction 58 aldosterone antagonists 58 1mg dose 58 Kaplan Meier curve 58 multivariable analysis 58 Peg IFN 58 IV bolus 58 receiving VICTRELIS 58 rivaroxaban 58 complete cytogenetic response 58 intravitreal injections 58 mg/m2 dose 58 non squamous NSCLC 58 PRIMO CABG2 58 carotid intima media 58 elagolix 58 xanthine oxidase inhibitor 58 angiotensin receptor blocker ARB 58 rNAPc2 58 viral kinetics 58 median PFS 58 mg TID 58 TYKERB 58 metastatic malignant melanoma 58 INCB# [003] 58 YMRS 58 Taxotere ® 58 neratinib 58 platelet inhibitor 58 ziprasidone 58 serum HCV RNA 58 histologies 58 HBeAg negative 58 rebleeding 58 interferon alfa 2b 58 SSc 58 adjunctive ABILIFY 58 renal insufficiency 58 #mg/day [001] 58 monotherapy 58 ZYVOX 58 fibrinolysis 58 #:# randomization 58 acute coronary syndromes 58 neutropaenia 58 logistic regression model 58 pharmacokinetic PK 58 fluorouracil 58 Study GL# 58 annualized relapse 58 bicifadine 58 Fibrillex TM 58 FASLODEX 58 Unified Parkinson Disease 58 BENICAR 58 fibrinolytic 58 amphotericin B 58 dyslipidaemia 58 LVSD 58 oxaliplatin Eloxatin 58 oblimersen 58 Pred Forte 58 blinded randomized placebo controlled 58 TMC# C# 58 RLAI 58 antihypertensive therapy 58 acute coronary syndrome 58 strontium ranelate 58 bi ventricular pacing 58 dyskinesia PD LID 58 TYGACIL 58 refractory ischemia 58 HMG CoA reductase inhibitor 58 XELOX 58 sorafenib Nexavar 58 atrioventricular valve 58 DES implantation 58 Tekamlo 58 Platinol 58 ischemic cardiovascular 58 darunavir ritonavir 58 multicenter randomized placebo controlled 58 CHOP chemotherapy 58 APPRAISE 58 postprocedure 58 Tolvaptan 58 carotid stenosis 58 urinary N telopeptide 58 muraglitazar 58 Atacand 58 distant metastasis 58 peginterferon 58 grade cervical intraepithelial 58 univariate analysis 58 divalproex sodium 58 GSK# [001] 58 amoxicillin clavulanate 58 NIH CPSI 58 primidone 58 preoperative chemotherapy 58 p = #.# [004] 58 BYSTOLIC 58 intravenous bisphosphonates 58 complete cytogenetic 58 active moiety 58 androgen deprivation 58 atherogenic dyslipidemia 58 nasopharyngitis headache 58 gemcitabine Gemzar ® 58 YERVOY 58 bupropion SR 58 micafungin 58 IOP lowering 58 μg dose 58 nephrotoxicity 58 8mg/kg 58 relapsing multiple sclerosis 58 FDA defined valvulopathy 58 oxcarbazepine 58 relapsed myeloma 58 Retisert TM 58 cytogenetic abnormalities 58 EDEMA3 trial 58 doxorubicin cyclophosphamide 58 TDF FTC 58 placebo controlled Phase 57 Pemetrexed 57 pretest probability 57 perioperative mortality 57 flutamide 57 venous thromboembolisms 57 MADIT II 57 goserelin 57 tenecteplase 57 NIHSS 57 metformin sulfonylurea 57 immunosuppressive regimen 57 #mg QD [001] 57 RE LY trial 57 plus glycoprotein IIb 57 stable angina 57 AIM HIGH 57 prospective multicenter study 57 briakinumab 57 proteinuria 57 phase IIb 57 HORIZONS AMI trial 57 TAXUS p value 57 fluoropyrimidine 57 romiplostim 57 NSTEMI 57 #mg dose [003] 57 transthoracic 57 cytoreductive surgery 57 covariate 57 omecamtiv mecarbil 57 RSD# oral 57 logistic regression analysis 57 stenoses 57 Treatment emergent adverse 57 carotid artery stenting 57 Flu Cy 57 nasopharyngitis 57 thiazolidinedione 57 meta regression 57 DAS# [002] 57 CDAI score 57 MabCampath 57 DLTs 57 GP IIb IIIa inhibitors 57 liver metastases 57 extracranial 57 plus GP IIb 57 zonisamide 57 INTEGRILIN ® 57 unstable angina 57 dose dexamethasone 57 HIV RNA 57 beclomethasone dipropionate 57 thrombocytopenia 57 abatacept 57 ULORIC 57 ZOLINZA 57 bolus dose 57 NNT = 57 dacetuzumab 57 pharmacodynamics PD 57 diameter stenosis 57 nonfatal cardiovascular 57 receiving INTRON 57 FluCAM arm 57 risperidone Risperdal 57 Zenvia ™ 57 tumor histology 57 GORE VIABAHN Endoprosthesis 57 Sustained virologic response 57 PSA nadir 57 tamsulosin 57 pioglitazone HCl 57 crizotinib PF # 57 Brief Psychiatric 57 biologic therapy 57 sUA 57 Y BOCS 57 Octreolin 57 oral ridaforolimus 57 beta blocker therapy 57 plus prednisone 57 stent thromboses 57 K ras mutations 57 VT VF 57 dexpramipexole 57 TACE 57 dose escalation Phase 57 eculizumab 57 discontinuations 57 REYATAZ ritonavir 57 lymphadenectomy 57 nilotinib 57 CVD mortality 57 Toxicities 57 arterial occlusion 57 pharmacodynamic endpoints 57 ORENCIA ® 57 RSD# iv 57 Edwards SAPIEN valve 57 sunitinib 57 interferon gamma 1b 57 hematological adverse 57 multivariate logistic regression 57 sirolimus 57 SSRI SNRI 57 paricalcitol 57 concomitant AEDs 57 canakinumab 57 colorectal liver metastases 57 nodular partial response 57 pomalidomide 57 statistically nonsignificant 57 locoregional disease 57 dobutamine 57 bezafibrate 57 alvimopan 57 lipid parameters 57 peg IFN 57 highly emetogenic 57 RAPAFLO R 57 FROVA 57 cardioembolic stroke 57 hypomagnesemia 57 WOMAC pain 57 sumatriptan naproxen sodium 57 cinacalcet 57 azathioprine 57 EXPAREL 57 Acute Myocardial Infarction 57 systemic corticosteroid 57 thrombolytic therapy 57 gemcitabine carboplatin 57 liposomal doxorubicin 57 AA Amyloidosis 57 Non inferiority 57 revascularisation 57 endoscopic gastric ulcers 57 postoperative morbidity 57 neostigmine 57 angiotensin converting enzyme inhibitor 57 pamidronate 57 ROCKET AF 57 Acute coronary syndromes 57 histologically confirmed 57 budesonide 57 concurrent chemoradiation 57 thymalfasin 57 metastatic renal cell carcinoma 57 leucopenia 57 ascending dose 57 clinicopathological features 57 MIST II 57 PRECISE 57 Combo Stent 57 prospective randomized multicenter 57 colesevelam HCl 57 syncopal 57 DMARDs 57 radiochemotherapy 57 oral FTY# 57 ACR# response 57 Venous thromboembolism 57 PFO migraine 57 lacosamide 57 oral corticosteroids 57 glufosfamide 57 neoadjuvant therapy 57 progression TTP 57 hyperacute 57 revascularization 57 QVAR R 57 fosbretabulin 57 liposomal amphotericin B 57 landmark ATHENA 57 Microplasmin 57 vidofludimus 57 ALLHAT 57 atheroma volume 57 antiplatelet therapy 57 FRAGMIN 57 HbA 1c 57 DULERA 57 malignant neoplasms 57 CLARITY study 57 VIIBRYD 57 palliation 57 keloid scarring 57 coronary intervention 57 LOVENOX R 57 virologic responses 57 phase IIb trial 57 argatroban 57 endometrial carcinoma 57 HER2 overexpression 57 #mg/m# [001] 57 Ereska 57 generalized tonic clonic seizures 57 CHAMPION PLATFORM 57 lintuzumab 57 SIMPADICO 57 piperacillin tazobactam 57 bivalirudin monotherapy 57 benazepril 57 #mg/m# [002] 57 anticoagulant warfarin 57 ADAS cog 57 chemoradiation therapy 57 response pCR 57 intraocular inflammation 57 Pharmacokinetic parameters 57 Prospective Randomized 57 etanercept 57 eculizumab therapy 57 Negative Syndrome